Global Markets Direct is a cutting-edge provider of market research and business consultancies for a wide range of customers worldwide.
A team of analytics is capable to produce all sorts of market information and carry out extensive industry research using unique data and reliable sources to let customers know who they are at the market. Global Markets Direct has profound analytical experience in researching the industries and preparing customized reports across many specific fields.
The company is distinguished by its high-quality consulting products and close inspection of the issues under study. Diligent efforts of the experts make every piece of business information an exclusive source of feasible solutions and valuable advice.
With a commitment to serve every client need, Global Markets Direct collects and interprets the materials for the analysis, uses methods of primary and secondary research and develops one of a kind data packages for global clients. They are able to cover the tones of industry-related information to assist customers in taking the right business decisions and developing their strategic plans.
Under the supervision of skillful managers and experts, business analysts produce reports that include:
- Product portfolio
- Potentially strong market reviews
- Competitive analytics
- Prospect partners
- Mergers and acquisitions project data
- Latest trends across a particular industry area
- Research and development strategies
- The analysis of new customers
- A set of remedial measures for projects
They will search for new partners and highlight the current business issues plus develop new strategies and tactical steps to help you take the lead in the industry where you operate.
Publications found:
5,853
Sort by:
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019
US$ 2,000.00
... Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2019
88 pages
Bone Fracture - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2019
75 pages
Ependymoma - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Ependymoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ependymoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2019
237 pages
Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2019
US$ 2,000.00
... . The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2019
58 pages
Muscle Atrophy - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Muscle Atrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2019
37 pages
Xerostomia - Pipeline Review, H2 2019
US$ 2,000.00
... and Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Xerostomia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
November 2019
37 pages
Fibromyalgia - Pipeline Review, H2 2019
US$ 2,000.00
... . The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
November 2019
111 pages
Bacillary Dysentery - Pipeline Review, H2 2019
US$ 2,000.00
Bacillary Dysentery - Pipeline Review, H2 2019 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bacillary Dysentery (Shigellosis) - Pipeline Review, H2 201...
November 2019
55 pages
Constipation - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
September 2019
111 pages
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Opioid-Induced Constipation (OIC) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
September 2019
52 pages
Reflux Esophagitis - Pipeline Review, H2 2019
US$ 2,000.00
Reflux Esophagitis - Pipeline Review, H2 2019 SUMMARY Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2019, provides an o...
September 2019
98 pages
P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H2 2019
US$ 3,500.00
... P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
61 pages
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019
US$ 3,500.00
... P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
50 pages
Encephalitis - Pipeline Review, H2 2019
US$ 2,000.00
... . The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies ...
August 2019
47 pages
Hypotension - Pipeline Review, H2 2019
US$ 2,000.00
... releases. The Hypotension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypotension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities ...
August 2019
54 pages
72 kDa Type IV Collagenase - Pipeline Review, H2 2019
US$ 3,500.00
... key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding 72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) development landscape Develop ...
August 2019
32 pages
Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019
US$ 3,500.00
... Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
88 pages
Bcl 2 Like Protein 1 - Pipeline Review, H2 2019
US$ 3,500.00
... Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
59 pages
Cathepsin K - Pipeline Review, H2 2019
US$ 3,500.00
... reviews Cathepsin K (Cathepsin O or Cathepsin O2 or Cathepsin X or CTSK or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
40 pages
Integrin Alpha 4 - Pipeline Review, H2 2019
US$ 3,500.00
... Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
87 pages
Integrin Beta 7 - Pipeline Review, H2 2019
US$ 3,500.00
... Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
54 pages
Intercellular Adhesion Molecule 1 - Pipeline Review, H2 2019
US$ 3,500.00
... Intercellular Adhesion Molecule 1 (Major Group Rhinovirus Receptor or CD54 or ICAM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
47 pages
Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2019
US$ 3,500.00
... Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources The report covers pipeline products ...
August 2019
44 pages
Mucin 1 - Pipeline Review, H2 2019
US$ 3,500.00
... reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development ...
August 2019
92 pages
Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019
US$ 3,500.00
... being developed by Companies/Universities. It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with ...
August 2019
119 pages
Peroxisome Proliferator Activated Receptor Delta - Pipeline Review, H2 2019
US$ 3,500.00
... also reviews key players involved in Peroxisome Proliferator Activated Receptor Delta (NUCI or Nuclear Hormone Receptor 1 or Nuclear Receptor Subfamily 1 Group C Member 2 or Peroxisome Proliferator Activated Receptor Beta or NR1C2 or PPARD) targeted therapeutics development with respective active and dormant ...
August 2019
106 pages
Sodium and Chloride Dependent Glycine Transporter 1 - Pipeline Review, H2 2019
US$ 3,500.00
... effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape Develop and design in-licensing ...
August 2019
31 pages
Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2019
US$ 3,500.00
... by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape Develop and ...
August 2019
99 pages
5' Nucleotidase - Pipeline Review, H2 2019
US$ 3,500.00
5' Nucleotidase - Pipeline Review, H2 2019 SUMMARY 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5?-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present...
August 2019
87 pages
Alpha Synuclein - Pipeline Review, H2 2019
US$ 3,500.00
Alpha Synuclein - Pipeline Review, H2 2019 SUMMARY Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normal...
August 2019
126 pages
Angiopoietin 1 Receptor - Pipeline Review, H2 2019
US$ 3,500.00
Angiopoietin 1 Receptor - Pipeline Review, H2 2019 SUMMARY According to the recently published report 'Angiopoietin 1 Receptor - Pipeline Review, H2 2019'; Angiopoietin 1 Receptor (Endothelial Tyros...
August 2019
141 pages
Integrin Beta 3 - Pipeline Review, H2 2019
US$ 3,500.00
Integrin Beta 3 - Pipeline Review, H2 2019 SUMMARY Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 24 molecules. Out of which approximatel...
August 2019
74 pages
Leptin Receptor - Pipeline Review, H2 2019
US$ 3,500.00
Leptin Receptor - Pipeline Review, H2 2019 SUMMARY Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 7 molecules. The latest report Leptin Receptor - Pipe...
August 2019
50 pages
Rho Associated Protein Kinase 1 - Pipeline Review, H2 2019
US$ 3,500.00
Rho Associated Protein Kinase 1 - Pipeline Review, H2 2019 SUMMARY According to the recently published report 'Rho Associated Protein Kinase 1 - Pipeline Review, H2 2019'; Rho Associated Protein Kin...
August 2019
37 pages
Smoothened Homolog - Pipeline Review, H2 2019
US$ 3,500.00
Smoothened Homolog - Pipeline Review, H2 2019 SUMMARY According to the recently published report 'Smoothened Homolog - Pipeline Review, H2 2019'; Smoothened Homolog (Protein Gx or SMO) pipeline Targ...
August 2019
85 pages
Toll Like Receptor 4 - Pipeline Review, H2 2019
US$ 3,500.00
Toll Like Receptor 4 - Pipeline Review, H2 2019 SUMMARY Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed...
August 2019
117 pages
